OPKO Health, Inc. (OPK) Stock

OPKO Health, Inc. (OPK) is a Healthcare stock trading at $1.42 (as of 2026-06-18), with a market capitalization of $1.10B and a trailing P/E of -5.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

OPKO Health, Inc. operates diagnostics and pharmaceuticals businesses. In diagnostics, it provides laboratory testing services through BioReference Laboratories and offers related services such as molecular, pathology, women’s health, and other specialized tests, along with point-of-care blood test and prostate cancer testing services. Its pharmaceutical segment develops and markets treatments including Rayaldee and other investigational therapies, serving patients and healthcare providers.

Valuation — source: SEC EDGAR (first-party)
Price	$1.42
Market Cap	$1.10B
P/E Ratio	-5.4
EV / EBITDA	-68.7
Price / Book	0.92
Price / Sales	1.90
DCF Value (model)	$-4.23
DCF Upside vs Price	-397.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$606.88M
Net Margin	-37.2%
Return on Equity	-17.7%
Debt / Equity	0.00
Current Ratio	3.61
Revenue Growth (YoY)	-17.2%
EPS Growth (YoY)	-30.0%
FCF Growth (YoY)	-44.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.30 (distress)
Piotroski F-Score	3/9 (weak)

Valuation vs Sector & Industry
Stock P/E	-5.4
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-125.8%
vs Industry	-131.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Buys (12mo)	34
Top Institutional Holder	BlackRock Fund Advisors ($105.37M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Phillip Frost
Employees	2,997
Country	US
IPO Date	1995-11-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.